MX370272B - Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer. - Google Patents

Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.

Info

Publication number
MX370272B
MX370272B MX2016011240A MX2016011240A MX370272B MX 370272 B MX370272 B MX 370272B MX 2016011240 A MX2016011240 A MX 2016011240A MX 2016011240 A MX2016011240 A MX 2016011240A MX 370272 B MX370272 B MX 370272B
Authority
MX
Mexico
Prior art keywords
chimeric antigen
antigen receptors
cancer immunotherapy
specific chimeric
derivedfrom
Prior art date
Application number
MX2016011240A
Other languages
English (en)
Spanish (es)
Other versions
MX2016011240A (es
Inventor
Galetto Roman
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectis filed Critical Cellectis
Publication of MX2016011240A publication Critical patent/MX2016011240A/es
Publication of MX370272B publication Critical patent/MX370272B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016011240A 2014-03-19 2015-03-19 Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer. MX370272B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201470137 2014-03-19
PCT/EP2015/055848 WO2015140268A1 (en) 2014-03-19 2015-03-19 Cd123 specific chimeric antigen receptors for cancer immunotherapy

Publications (2)

Publication Number Publication Date
MX2016011240A MX2016011240A (es) 2017-01-11
MX370272B true MX370272B (es) 2019-12-09

Family

ID=58702463

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016011240A MX370272B (es) 2014-03-19 2015-03-19 Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
MX2019012244A MX2019012244A (es) 2014-03-19 2016-08-30 Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019012244A MX2019012244A (es) 2014-03-19 2016-08-30 Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.

Country Status (17)

Country Link
US (3) US9944709B2 (enExample)
EP (2) EP3569619B1 (enExample)
JP (2) JP6689202B2 (enExample)
KR (1) KR102157411B1 (enExample)
CN (1) CN106103490B (enExample)
AU (1) AU2015233461B2 (enExample)
CA (1) CA2943008C (enExample)
DK (2) DK3119807T3 (enExample)
ES (2) ES2877606T3 (enExample)
HU (1) HUE045480T2 (enExample)
IL (1) IL247172B (enExample)
MX (2) MX370272B (enExample)
PL (1) PL3119807T3 (enExample)
PT (1) PT3119807T (enExample)
RU (1) RU2727290C2 (enExample)
TR (1) TR201910814T4 (enExample)
WO (1) WO2015140268A1 (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
TR201910814T4 (tr) * 2014-03-19 2019-08-21 Cellectis Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
PL3183268T3 (pl) 2014-08-19 2020-09-07 Novartis Ag Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
JP2018504145A (ja) 2015-01-26 2018-02-15 セレクティスＣｅｌｌｅｃｔｉｓ 再発性／難治性急性骨髄性リンパ腫または芽球性形質細胞様樹状細胞新生物を処置するための、ｃｄ１２３に結合するキメラ抗原受容体を賦与された、操作されたｔ細胞受容体ノックアウト免疫細胞
CA2978840A1 (en) 2015-03-11 2016-09-15 Cellectis Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
EP3270936A4 (en) 2015-03-17 2018-08-08 Chimera Bioengineering Inc. Smart car devices, de car polypeptides, side cars and uses thereof
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
BR112018002600A2 (pt) * 2015-08-11 2018-10-23 Cellectis células para imunoterapia modificadas para direcionamento ao antígeno cd38 e para inativação do gene cd38
GB201518136D0 (en) * 2015-10-14 2015-11-25 Glaxosmithkline Ip Dev Ltd Novel chimeric antigen receptors
DK3368571T5 (da) * 2015-10-30 2024-09-30 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
US10894093B2 (en) 2016-04-15 2021-01-19 Cellectis Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
WO2017178586A1 (en) 2016-04-15 2017-10-19 Cellectis A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
EP3458077A4 (en) 2016-05-17 2020-04-01 Chimera Bioengineering Inc. METHODS OF MANUFACTURING NEW AREAS OF ANTIGEN BINDING
CN107793481A (zh) * 2016-08-31 2018-03-13 南京传奇生物科技有限公司 一种靶向人cd123的嵌合受体配体及其应用
CN112481217A (zh) 2016-09-01 2021-03-12 嵌合体生物工程公司 Gold优化的car t-细胞
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
EP3529347A1 (en) 2016-10-19 2019-08-28 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
AU2017363278B2 (en) 2016-11-22 2022-10-27 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
EP3570850A4 (en) * 2017-01-18 2020-10-14 Thalia Papayannopoulou PACKAGING COMPOSITIONS AND METHODS FOR A TRANSPLANT RECEIVER
JP7386082B2 (ja) 2017-02-28 2023-11-24 ブイオーアール バイオファーマ インコーポレーテッド 系統特異的タンパク質の阻害のための組成物および方法
AU2018246378A1 (en) * 2017-03-31 2019-10-17 Cellectis Sa New universal chimeric antigen receptor T cells specific for CD22
CA3059643A1 (en) 2017-04-13 2018-10-18 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
KR20200019231A (ko) * 2017-06-22 2020-02-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 조절 면역 세포를 제조하기 위한 방법 및 이의 용도
US12496310B2 (en) * 2017-06-30 2025-12-16 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy
CA3068636A1 (en) 2017-06-30 2019-01-03 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer
US12178830B2 (en) 2017-06-30 2024-12-31 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer
AU2018292181B2 (en) 2017-06-30 2025-04-10 Cellectis Cellular immunotherapy for repetitive administration
WO2019084495A1 (en) * 2017-10-27 2019-05-02 The Trustees Of The University Of Pennsylvania IDENTIFICATION OF EPIGENETIC AND TRANSCRIPTIONAL TARGETS TO PREVENT AND REVERSE T-LYMPHOCYTE EXHAUST
GB201719169D0 (en) 2017-11-20 2018-01-03 Univ College Cardiff Consultants Ltd Novel T-cell receptor and ligand
US20200352999A1 (en) * 2017-11-22 2020-11-12 La Jolla Institute For Allergy And Immunology Use and production of engineered immune cells to disrupt nfat-ap1 pathway transcription factors
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
CA3086267A1 (en) 2017-12-29 2019-07-04 Cellectis Method for improving production of car t cells
US20230183313A1 (en) 2018-02-11 2023-06-15 Jiangsu Hengrui Medicine Co., Ltd. Isolated chimeric antigen receptor, modified t cell comprising same and use thereof
CN111989108B (zh) 2018-02-13 2024-07-16 嵌合体生物工程公司 利用rna去稳定元件协调基因表达
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
WO2019183094A1 (en) * 2018-03-19 2019-09-26 The Regents Of The University Of Michigan Compositions and methods for t-cell and cytokine activation
KR20190141511A (ko) * 2018-06-14 2019-12-24 주식회사 녹십자랩셀 신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포
JP2022520138A (ja) 2018-08-28 2022-03-29 ブイオーアール バイオファーマ インコーポレーテッド 遺伝子操作された造血幹細胞およびそれらの使用
CN113260630B (zh) * 2018-09-20 2024-05-24 莱蒂恩技术公司 用于用抗cd123免疫治疗来治疗癌症的组合物和方法
CN109266618B (zh) * 2018-10-18 2021-04-23 赛元生物科技(杭州)有限公司 能够靶向肿瘤细胞的巨噬细胞及其制备方法
AU2019371243A1 (en) * 2018-10-30 2021-05-27 Bruker Spatial Biology, Inc. Bispecific CD123 x CD3 diabodies for the treatment of hematologic malignancies
CN113347991B (zh) * 2019-01-23 2024-07-30 美天施生物科技有限两合公司 用于消除和增强受试者骨髓中造血干细胞植入的组合物的组合
US20220160771A1 (en) 2019-04-10 2022-05-26 Iulia Diaconu Flt3-specific chimeric antigen receptors and methods of using the same
CA3136551A1 (en) 2019-04-12 2020-10-15 Board Of Regents, The University Of Texas System Methods for producing regulatory b cells and uses thereof
CN114786686A (zh) 2019-08-18 2022-07-22 嵌合体生物工程公司 Gold控制的转基因的联合疗法
JP2022546505A (ja) 2019-08-28 2022-11-04 ブイオーアール バイオファーマ インコーポレーテッド Ｃｄ１２３改変ための組成物および方法
WO2022047165A1 (en) 2020-08-28 2022-03-03 Vor Biopharma Inc. Compositions and methods for cd123 modification
CN112079927B (zh) * 2020-09-18 2021-12-28 西安桑尼赛尔生物医药有限公司 一种cd123结合蛋白、含其的car及其应用
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
CN112646033B (zh) * 2020-12-16 2022-04-12 北京艺妙神州医药科技有限公司 靶向cd123的嵌合抗原受体及其用途
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
AU2021414400A1 (en) 2020-12-31 2023-08-17 Innate Pharma Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
WO2022266075A1 (en) 2021-06-14 2022-12-22 Caribou Biosciences, Inc. Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain
EP4376877A2 (en) 2021-07-29 2024-06-05 Vor Biopharma Inc. Chimeric antigen receptors for treatment of cancer
EP4376958A1 (en) 2021-07-30 2024-06-05 Affimed GmbH Duplexbodies
WO2023020471A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Cd123-targetting antibodies and uses thereof in cancer therapies
JP2024543822A (ja) 2021-11-03 2024-11-26 アフィメド ゲーエムベーハー 二重特異性ｃｄ１６ａバインダー
US20250064933A1 (en) * 2021-12-30 2025-02-27 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors comprising a pdz binding motif
CN118574646A (zh) * 2022-01-19 2024-08-30 上海优替济生生物医药有限公司 环状rna及其用途
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
JP7747911B2 (ja) 2022-05-27 2025-10-01 サノフイ ＮＫｐ４６に結合するナチュラルキラー（ＮＫ）細胞エンゲージャー及びＦＣエンジニアリングを有するＢＣＭＡ変異体
CN117511882A (zh) * 2022-08-03 2024-02-06 浙江大学医学院附属第一医院 一种通用型免疫效应细胞及其制备方法和应用
WO2024094004A1 (zh) * 2022-11-03 2024-05-10 重庆精准生物技术有限公司 靶向cd123的全人源抗体及其应用
WO2024196796A1 (en) * 2023-03-17 2024-09-26 Cartesian Therapeutics, Inc. Intracellular signaling and costimulatory domains adapted for prolonged expression of chimeric antigen receptors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
AU6704794A (en) 1993-04-13 1994-11-08 Sloan-Kettering Institute For Cancer Research Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
WO1997033988A1 (en) 1996-03-12 1997-09-18 Sloan-Kettering Institute For Cancer Research Double mutants of dihydrofolate reductase and methods of using same
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
ES2302726T3 (es) 2000-02-24 2008-08-01 Invitrogen Corporation Estimulacion y concentracion simultanea de celulas.
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CN1826408B (zh) 2003-03-14 2011-01-26 塞托·帕尔斯科技公司 大容量离体电穿孔法
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
EP2332994A1 (en) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
GB2481983A (en) 2010-07-12 2012-01-18 Hart Fenton & Co Ltd A ship including a gas tank room
WO2012012667A2 (en) * 2010-07-21 2012-01-26 Sangamo Biosciences, Inc. Methods and compositions for modification of a hla locus
AU2011319725A1 (en) 2010-10-27 2013-05-30 Cellectis Method for increasing the efficiency of double-strand break-induced mutagenesis
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
SG10201602651YA (en) 2011-04-05 2016-05-30 Cellectis Method for the generation of compact tale-nucleases and uses thereof
AU2013221672B2 (en) 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
HK1203393A1 (en) * 2012-04-11 2015-10-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
KR102247979B1 (ko) 2012-05-25 2021-05-04 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
US9573988B2 (en) * 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
TWI654206B (zh) * 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
JP2017504601A (ja) * 2013-12-20 2017-02-09 セレクティスＣｅｌｌｅｃｔｉｓ 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法
TR201910814T4 (tr) * 2014-03-19 2019-08-21 Cellectis Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
US20180134795A1 (en) * 2014-06-17 2018-05-17 Cellectis Cd123 specific multi-chain chimeric antigen receptor
AU2015367317A1 (en) * 2014-12-17 2017-06-01 Cellectis Inhibitory chimeric antigen receptor (iCAR or N-CAR) expressing non-T cell transduction domain
JP2018504145A (ja) * 2015-01-26 2018-02-15 セレクティスＣｅｌｌｅｃｔｉｓ 再発性／難治性急性骨髄性リンパ腫または芽球性形質細胞様樹状細胞新生物を処置するための、ｃｄ１２３に結合するキメラ抗原受容体を賦与された、操作されたｔ細胞受容体ノックアウト免疫細胞

Also Published As

Publication number Publication date
CA2943008A1 (en) 2015-09-24
MX2016011240A (es) 2017-01-11
PT3119807T (pt) 2019-09-04
EP3119807A1 (en) 2017-01-25
JP6942217B2 (ja) 2021-09-29
JP6689202B2 (ja) 2020-04-28
EP3119807B1 (en) 2019-04-24
IL247172A0 (en) 2016-09-29
US20190002573A1 (en) 2019-01-03
WO2015140268A1 (en) 2015-09-24
CN106103490A (zh) 2016-11-09
RU2727290C2 (ru) 2020-07-21
TR201910814T4 (tr) 2019-08-21
AU2015233461B2 (en) 2020-03-19
US20170183413A1 (en) 2017-06-29
PL3119807T3 (pl) 2019-09-30
JP2017509342A (ja) 2017-04-06
RU2016140855A (ru) 2018-04-20
EP3569619A1 (en) 2019-11-20
DK3569619T3 (da) 2021-06-14
US10988541B2 (en) 2021-04-27
ES2877606T3 (es) 2021-11-17
US20210163612A1 (en) 2021-06-03
EP3569619B1 (en) 2021-05-26
CA2943008C (en) 2021-03-30
ES2740903T3 (es) 2020-02-07
HUE045480T2 (hu) 2019-12-30
JP2020156482A (ja) 2020-10-01
RU2016140855A3 (enExample) 2018-11-16
DK3119807T3 (da) 2019-07-15
US11919961B2 (en) 2024-03-05
CN106103490B (zh) 2020-03-03
KR20170002389A (ko) 2017-01-06
IL247172B (en) 2021-08-31
AU2015233461A1 (en) 2016-08-25
US9944709B2 (en) 2018-04-17
MX2019012244A (es) 2019-12-19
KR102157411B1 (ko) 2020-09-18
BR112016019643A2 (pt) 2017-10-24

Similar Documents

Publication Publication Date Title
MX2019012244A (es) Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
WO2015150526A3 (en) Cd33 specific chimeric antigen receptors for cancer immunotherapy
MX381908B (es) Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.
MX2017001211A (es) Receptores de antigenos quimericos ror1 (ntrkr1) especificos para inmunoterapia del cancer.
MX2017001229A (es) Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer.
MX370173B (es) Células efectoras inmunitarias modificadas genéticamente con el receptor de antígenos quiméricos específico de cs1.
MX2019001184A (es) Anticuerpos anti-idiotípicos y métodos relacionados.
WO2017147383A8 (en) Modified cells for immunotherapy
EP4414380A3 (en) Universal anti-cd22 chimeric antigen receptor engineered immune cells
PH12018501042A1 (en) Antibodies and antibody fragments for site-specific conjugation
PH12015502479B1 (en) Cd19 specific chimeric antigen receptor and uses thereof
MX2020003046A (es) Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.
MY176294A (en) Antibodies comprising chimeric constant domains
PH12016502491A1 (en) Bispecific heterodimeric diabodies and uses thereof
CL2016002195A1 (es) Receptor antigénico quimérico car con dominios de unión a antígenos a la región constante del receptor de células t beta
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
AR104718A1 (es) Receptores de antígenos quiméricos específicos de anti-gd3 para inmunoterapias contra el cáncer
MX2021001711A (es) Proteínas biespecíficas modificadas.
MX379210B (es) Acoplador trifuncional de antígeno de células t y métodos y usos del mismo.
MX2016012713A (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
AU2016259730A8 (en) Claudin-18.2-specific immunoreceptors and T cell epitopes
AU2018338423A1 (en) Novel anti-HLA-A2 antibodies and uses thereof
MX382952B (es) Métodos de producción de proteínas de cadena doble en bacterias.
MX2020000595A (es) Regiones de unión al antígeno contra dominios de fibronectina tipo iii y métodos para su uso.
NZ750009A (en) Antibodies comprising chimeric constant domains

Legal Events

Date Code Title Description
FG Grant or registration